MAIOLINO, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.090
AS - Asia 1.282
EU - Europa 994
SA - Sud America 239
AF - Africa 194
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 12
Totale 7.833
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.984
SG - Singapore 467
CN - Cina 319
HK - Hong Kong 214
IT - Italia 214
BR - Brasile 172
DE - Germania 119
SE - Svezia 116
FI - Finlandia 89
GB - Regno Unito 72
PL - Polonia 63
VN - Vietnam 60
NL - Olanda 48
RU - Federazione Russa 41
FR - Francia 40
IN - India 37
UA - Ucraina 34
CA - Canada 16
IQ - Iraq 14
ZA - Sudafrica 14
AT - Austria 13
AZ - Azerbaigian 13
HN - Honduras 13
TR - Turchia 12
AR - Argentina 11
EC - Ecuador 11
PA - Panama 11
TN - Tunisia 11
UZ - Uzbekistan 11
KR - Corea 10
PY - Paraguay 10
BG - Bulgaria 9
CI - Costa d'Avorio 9
ES - Italia 9
IR - Iran 9
MK - Macedonia 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
MA - Marocco 8
SO - Somalia 8
XK - ???statistics.table.value.countryCode.XK??? 8
AU - Australia 7
BF - Burkina Faso 7
BS - Bahamas 7
CV - Capo Verde 7
GA - Gabon 7
GN - Guinea 7
IE - Irlanda 7
JM - Giamaica 7
KG - Kirghizistan 7
MD - Moldavia 7
MZ - Mozambico 7
PE - Perù 7
PK - Pakistan 7
SI - Slovenia 7
BO - Bolivia 6
BY - Bielorussia 6
BZ - Belize 6
CR - Costa Rica 6
ET - Etiopia 6
GH - Ghana 6
GR - Grecia 6
HU - Ungheria 6
KH - Cambogia 6
ML - Mali 6
PG - Papua Nuova Guinea 6
PH - Filippine 6
PT - Portogallo 6
RO - Romania 6
SA - Arabia Saudita 6
SK - Slovacchia (Repubblica Slovacca) 6
AL - Albania 5
BE - Belgio 5
CM - Camerun 5
CO - Colombia 5
CY - Cipro 5
DO - Repubblica Dominicana 5
EE - Estonia 5
ID - Indonesia 5
JP - Giappone 5
KE - Kenya 5
LU - Lussemburgo 5
LY - Libia 5
ME - Montenegro 5
MN - Mongolia 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
PS - Palestinian Territory 5
RE - Reunion 5
UG - Uganda 5
AF - Afghanistan, Repubblica islamica di 4
AM - Armenia 4
BD - Bangladesh 4
CD - Congo 4
CG - Congo 4
CU - Cuba 4
CW - ???statistics.table.value.countryCode.CW??? 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
EG - Egitto 4
Totale 7.673
Salva come PNG Salva come JPEG
Città #
Fairfield 885
Ashburn 491
Woodbridge 454
Chandler 361
Houston 341
Seattle 321
Ann Arbor 296
Singapore 288
Cambridge 268
Wilmington 266
Hong Kong 206
Santa Clara 153
Boardman 104
Jacksonville 97
Beijing 89
Princeton 81
San Diego 76
Padova 72
Medford 57
Roxbury 53
Bytom 52
Des Moines 44
Helsinki 44
Munich 41
Nanjing 37
Dong Ket 35
New York 35
Jinan 19
Guangzhou 18
London 17
Baku 12
Milan 12
Los Angeles 11
Falkenstein 10
Hebei 10
Panama City 10
São Paulo 10
Tashkent 10
Boston 9
Hefei 9
Shenyang 9
Turku 9
Abidjan 8
Changsha 8
Ho Chi Minh City 8
Nuremberg 8
Rome 8
Bishkek 7
Conakry 7
Istanbul 7
Jiaxing 7
Nanchang 7
Padua 7
Redwood City 7
Seoul 7
Atlanta 6
Cagliari 6
Codognè 6
Council Bluffs 6
Dublin 6
Hangzhou 6
Hanoi 6
Johannesburg 6
Libreville 6
Maputo 6
Pristina 6
San José 6
Vienna 6
Accra 5
Addis Ababa 5
Brooklyn 5
Chicago 5
Curitiba 5
Kunming 5
Lanzhou 5
Nairobi 5
Nassau 5
Ouagadougou 5
Phnom Penh 5
Port Moresby 5
Quito 5
Shanghai 5
Sofia 5
Toronto 5
Tripoli 5
Ulan Bator 5
Amsterdam 4
Asunción 4
Auckland 4
Baghdad 4
Bamako 4
Baotou 4
Belize City 4
Brazzaville 4
Bucharest 4
Cape Town 4
Cayenne 4
Cochabamba 4
Dakar 4
Dubai 4
Totale 5.742
Salva come PNG Salva come JPEG
Nome #
PTH Modulation by Aldosterone and Angiotensin II is Blunted in Hyperaldosteronism and Rescued by Adrenalectomy 323
Quantitative Value of Aldosterone-Renin Ratio for Detection of Aldosterone-Producing Adenoma: The Aldosterone-Renin Ratio for Primary Aldosteronism (AQUARR) Study 209
A sleep apnoea questionnaire predicts organ damage in hypertensive patients 188
Design of a study to investigate the mechanisms of obstructive sleep apnoea by means of drug-induced sleep endoscopy 188
The Intra-Procedural Cortisol Assay During Adrenal Vein Sampling: Rationale and Design of a Randomized Study (I-Padua) 175
Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. 169
Proinflammatory/profibrotic effects of aldosterone in Gitelman’s syndrome, a human model opposite to hypertension 163
Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term 161
High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertension. 159
Assessment of the Quantitative Value Usefulness of the Aldosterone-Renin Ratio (ARR) for Primary Aldosteronism (AQUARR) Study 158
Macrolides for KCNJ5–mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism 155
Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. 145
Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients. 141
Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone–renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design 139
Subtyping of primary aldosteronism with adrenal vein sampling: Hormone- and side-specific effects of cosyntropin and metoclopramide 138
Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling? 138
Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization 133
Cure with cryoablation of arterial hypertension due to a renin-producing tumor. 132
Antibodies to malondialdehyde oxidized low-density lipoproteins predict long term cardiovascular mortality in high risk patients. 129
Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients 129
Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women 128
In Patients with Chronic Kidney Disease Short Term Blood Pressure Variability is Associated with the Presence and Severity of Sleep Disorders 128
A meta-analysis of somatic KCNJ5 K+ channel mutations in 1636 patients with an aldosterone-producing adenoma 128
Daily green tea extract supplementation reduces prothrombotic and inflammatory states in dialysis patients 127
Under treatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study 126
Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble 126
Gαq/p63RhoGEF interaction in RhoA/Rho kinase signaling: investigation in Gitelman’s syndrome and implications with hypertension 124
Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension 121
Relationship of early carotid artery disease with lipoprotein (a), apolipoprotein B, and fibrinogen in asymptomatic essential hypertensive patients and normotensive subjects 119
Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women. 118
Atrial fibrillation as presenting sign of primary aldosteronism: Results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study 117
Resolution of Drug-Resistant Hypertension by Adrenal Vein Sampling-guided Adrenalectomy: A Proof-of-Concept Study 117
The subtyping of primary aldosteronism by adrenal vein sampling: Sequential blood sampling causes factitious lateralization 110
The T-786 C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in caucasian patients of the GENICA study 109
Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives 108
The Time has Come for Systematic Screening for Primary Aldosteronism in All Hypertensives 107
LB02.07: EFFECT OF ACUTE DA2 DOPAMINERGIC RECEPTOR BLOCKADE ON PERFORMANCE OF ADRENAL VEIN SAMPLING FOR SUBTYPING OF PRIMARY ALDOSTERONISM 107
Androstenedione and 17-α-Hydroxyprogesterone Are Better Indicators of Adrenal Vein Sampling Selectivity Than Cortisol 106
Oxidative stress in hypertension and cardiovascular-renal remodeling:focus on the renin-angiotensin-aldosterone system 106
Uric acid and cardiovascular-renal disease risk. Insights from a human model opposite to hypertension 104
The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism 100
Macrolides Blunt Aldosterone Biosynthesis: A Proof-of-Concept Study in KCNJ5 Mutated Adenoma Cells Ex Vivo 99
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. 98
Recent advances in the diagnosis and management of obstructive sleep apnea 97
To reconsider (limit) the use of phosphate based food and beverages additives. A real need for health preservation. 95
Adrenal Venous Sampling: Where Do We Stand? 95
Is there an increased heme oxygenase-1 behind the antioxidant effects of green tea on blood pressure and sympathoexcitation reduction? 94
Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients 92
Primary aldosteronism in elderly, old, and very old patients 91
Comparative study at computed tomography angiography and intravascular ultrasound of coronary atherosclerotic plaques 91
The Molecular Basis of the Interplay between Endothelin-1 and Nitric Oxide and its Relevance for Atherosclerosis and Arterial and Pulmonary Hypertension. 90
The cardiovascular consequences of hyperaldosteronism 90
Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study 87
Arterial Hypertension, Aldosterone, and Atrial Fibrillation 85
Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism 85
Magnesium, cardiovascular-renal disease and the Gitelman's syndrome paradox. 82
New insights on the renal protective effects of mineralocorticoid receptor antagonists. 81
-786C and G894T variants of the Endothelial Nitric Oxide Synthase Gene and training-induced correction of endothelial dysfunction in coronary artery disease patients. 80
Survival and rehospitalization in patients with severe ischemic mitral regurgitation and multivessel coronary artery disease undergoing different treatment 75
Excessive daytime sleepiness does not correlate with sympathetic nervous system activation and arterial stiffening in patients with mild-to-moderate obstructive sleep apnoea: A proof-of-principle study 75
Effects of insomnia and restless legs syndrome on sleep arterial blood pressure: A systematic review and meta-analysis 74
Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines! 72
Moderate-to-severe ischeamic mitral regurgitation and multivessel coronary artery disease: impact of different treatment on survival and rehospitalization 70
Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure 65
The role of oxidized low-density lipoproteins in atherosclerosis: The myths and the facts 62
Excess arterial damage in hyperaldosteronism: Further evidence from pressure wave analysis 56
Excessive daytime sleepiness, sympathetic nervous system activation and arterial stiffening in patients with mild-to-moderate obstructive sleep apnoea. Reply 52
The Molecular Basis of the Interplay Interventional approach to reduce thromboembolic risk in patients with atrial fibrillation ineligible for oral anticoagulation 51
International multicenter survey on screening and confirmatory testing in primary aldosteronism 41
Totale 7.933
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.927
article - articoli 26.935
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 366
Totale 55.228
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.071 0 0 43 87 33 40 87 86 120 300 99 176
2021/2022959 13 90 88 83 92 79 51 102 53 25 73 210
2022/2023708 142 82 26 81 104 84 6 52 86 13 25 7
2023/2024327 18 43 51 29 16 41 22 16 8 15 26 42
2024/20251.545 9 106 87 61 223 28 97 133 93 61 242 405
2025/20261.108 320 468 320 0 0 0 0 0 0 0 0 0
Totale 7.933